Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel

Background: Brexucabtagene autoleucel (brexu-cel) is the first CD19 chimeric antigen receptor T-cell (CAR T) therapy approved for use in patients (pts) with relapsed mantle cell lymphoma (MCL). The ZUMA-2 trial demonstrated that brexu-cel induces durable remissions in these pts with an ORR of 85% (5...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.1756-1756
Hauptverfasser:	Romancik, Jason T., Goyal, Subir, Gerson, James N, Ballard, Hatcher J, Sawalha, Yazeed, Bond, David A., Rogalski, Michael Joseph, Greenwell, Irl Brian, van Besien, Koen, Yamshon, Samuel, Karmali, Reem, Nizamuddin, Imran, Torka, Pallawi, Chow, Victor A., Shadman, Mazyar, Ghosh, Nilanjan, Moyo, Tamara K., Fenske, Timothy S., Rezazadeh, Alexandra, Grover, Natalie S, Maddocks, Kami J., Jacobson, Caron, Cohen, Jonathon B.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!